Del.icio.us
Google
Yahoo MyWeb
Facebook
ChemoCentryx Overview
ChemoCentryx discovers, develops and commercializes new medicines for inflammatory disorders, cancer, autoimmune and infectious diseases by targeting the chemokine system, the master regulator of immune function. The Company is recognized as a world leader in biology, drug discovery and development based on the chemokine system. ChemoCentryx is developing first-in-class, oral therapies for...More»
ChemoCentryx discovers, develops and commercializes new medicines for inflammatory disorders, cancer, autoimmune and infectious diseases by targeting the chemokine system, the master regulator of immune function. The Company is recognized as a world leader in biology, drug discovery and development based on the chemokine system. ChemoCentryx is developing first-in-class, oral therapies for diseases such as inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis and cancer. ChemoCentryx distinguishes itself through unparalleled chemokine system expertise, innovative technologies and a product-driven approach, which has yielded several exciting drug candidates and the largest pipeline of chemokine-based drugs in the industry.«Less
Key People
Management
Board of Directors
Funding
| Date | Type | Capital Amount | Post-Money Valuation | Investors |
|---|---|---|---|---|
| 08/2006 | Series C | 17.7M | Unknown | |
| 03/2007 | Series D | 30M | 188M | |
| 09/2008 | Series E | 50M | Unknown |
|
Products
| Name: | Traficet-EN |
| Product URL: | http://www.chemocentryx.com/product/CCR9.html |
| Description: | Traficet-EN is intended to control the inappropriate immune system response underlying Crohn's disease by inhibiting the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed predominately by T-cells, a subset of the body's immune cells that migrate selectively to the digestive tract. Studies have shown that when CCR9, or its chemokine ligand CCL25 (previously known as TECK), are over-expressed, the migration of T-cells to the small and large intestine causes persistent inflammation. CCR9 positive T-cells have been shown to play a role in Crohn's disease and other gastrointestinal tract inflammatory disorders such as ulcerative colitis and celiac disease. |
| Screenshots: |
|
Competitors
Profile
OpinionsRelated Companies
Page Information
02/24/2009 11:03AM by dylanb
User Opinions
Bulls vs. Bears (0)
| Bullish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to succeed | ||||
| Bearish Opinions (0) | ||||
|---|---|---|---|---|
| Be the first to tell us why they are destined to stumble. | ||||
Discussions (0)
Start a New Discussion
Opinion Poll
View All Opinions »
Similar Companies
View All Similar »Web Metrics
View All Web Metrics »
| Alexa Rank: | n/a |  |
n/a |
| Yahoo Search Results: | n/a | ||
News & Blogs
View All News »- Latest
- Most Popular
- Submit a Story »
Waiting for IPO, ChemoCentryx Raises $50 Million from Glaxo
Oct 2, 2008 - 0 comments
ChemoCentryx on Twitter
Twitter Search »Discussions
View All Discussions »There are no discussions right now.
Recent Contributors
There are no recent contributors to this company.
Related Jobs
loading...